Form 4 Filing for Andrew Jacob Silver

This filing details stock options and restricted stock units granted to Andrew Jacob Silver, Chief Financial Officer of CRISPR Therapeutics AG. The grants occurred between November 2018 and October 2026, with vesting schedules varying from immediate to over several years. The filing also includes a Power of Attorney document, appointing specific individuals to act on Mr. Silver's behalf for SEC filings related to his securities holdings and transactions with the company. This power of attorney supersedes any previous arrangements and remains in effect until Mr. Silver is no longer required to file such forms or until earlier revoked.